Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

1.

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.

Johnson ML, Riely GJ, Rizvi NA, Azzoli CG, Kris MG, Sima CS, Ginsberg MS, Pao W, Miller VA.

J Thorac Oncol. 2011 Jun;6(6):1128-31. doi: 10.1097/JTO.0b013e3182161508.

PMID:
21623279
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
[PubMed - indexed for MEDLINE]
3.

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Riely GJ.

J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S146-9. doi: 10.1097/JTO.0b013e318174e96e. Review.

PMID:
18520300
[PubMed - indexed for MEDLINE]
4.

Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.

Xu Y, Liu H, Chen J, Zhou Q.

Cancer Biol Ther. 2010 Apr 15;9(8):572-82. Epub 2010 Apr 26. Review.

PMID:
20404520
[PubMed - indexed for MEDLINE]
Free Article
5.

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.

Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu L, Yin Y, Shu Y.

PLoS One. 2013;8(3):e59314. doi: 10.1371/journal.pone.0059314. Epub 2013 Mar 21. Review.

PMID:
23555654
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

Rosell R, Viteri S, Molina MA, Benlloch S, Taron M.

Curr Opin Oncol. 2010 Mar;22(2):112-20. doi: 10.1097/CCO.0b013e32833500d2. Review.

PMID:
19949333
[PubMed - indexed for MEDLINE]
7.

Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.

Ready N.

Semin Oncol. 2005 Apr;32(2 Suppl 3):S35-41. Review.

PMID:
16015534
[PubMed - indexed for MEDLINE]
8.

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.

Karamouzis MV, Grandis JR, Argiris A.

JAMA. 2007 Jul 4;298(1):70-82. Review.

PMID:
17609492
[PubMed - indexed for MEDLINE]
9.

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Engelman JA, Jänne PA.

Clin Cancer Res. 2008 May 15;14(10):2895-9. doi: 10.1158/1078-0432.CCR-07-2248. Review.

PMID:
18483355
[PubMed - indexed for MEDLINE]
Free Article
10.

The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients.

Kruser TJ, Traynor AM, Wheeler DL.

Expert Opin Investig Drugs. 2011 Feb;20(2):305-7. doi: 10.1517/13543784.2011.550873. Epub 2011 Jan 5. Review.

PMID:
21204748
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Metabolism considerations for kinase inhibitors in cancer treatment.

Duckett DR, Cameron MD.

Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1175-93. doi: 10.1517/17425255.2010.506873. Review.

PMID:
20684746
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk